TY - JOUR
T1 - Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer
AU - Ishimoto, Osamu
AU - Sugawara, Shunichi
AU - Inoue, Akira
AU - Ishida, Takashi
AU - Munakata, Mitsuru
AU - Koinumaru, Sadahiro
AU - Hasegawa, Yukihiro
AU - Suzuki, Toshiro
AU - Miki, Hiroshi
AU - Saijo, Yasuo
AU - Nukiwa, Toshihiro
PY - 2006/11
Y1 - 2006/11
N2 - BACKGROUND: The combination of carboplatin and docetaxel has been considered one of the standard treatments for advanced non-small cell lung cancer (NSCLC). To investigate a safer and more convenient schedule for outpatient, we conducted a phase II study to evaluate the efficacy and the safety of carboplatin plus biweekly docetaxel for advanced NSCLC. PATIENTS AND METHODS: Patients with stage IIIB, IV, or postoperative recurrent NSCLC with good performance status were administered docetaxel at a dose of 35 mg/m on days 1 and 15 and carboplatin at an area under the curve (AUC) of 6 on day 1 every 4 weeks for at least three cycles. RESULTS: Fifty patients were treated with median of three cycles (range 1-6). Grade 3/4 toxicities included neutropenia in 18 patients (36%), thrombocytopenia in 4 patients (8%), and anemia in 10 patients (20%). No patient experienced febrile neutropenia. Nonhematological toxicities were also mild to moderate, and there were no treatment-related deaths. The overall response rate was 30%, and the disease control rate was 70%. Among the elderly population, 54% of patients achieved partial response. Median progression-free survival was 4.8 months, and median overall survival was 11.8 months. CONCLUSIONS: Biweekly docetaxel plus carboplatin has a similar efficacy and lower toxicity compared with a standard triweekly regimen of docetaxel plus carboplatin, which is a suitable regimen for outpatients, including elderly patients.
AB - BACKGROUND: The combination of carboplatin and docetaxel has been considered one of the standard treatments for advanced non-small cell lung cancer (NSCLC). To investigate a safer and more convenient schedule for outpatient, we conducted a phase II study to evaluate the efficacy and the safety of carboplatin plus biweekly docetaxel for advanced NSCLC. PATIENTS AND METHODS: Patients with stage IIIB, IV, or postoperative recurrent NSCLC with good performance status were administered docetaxel at a dose of 35 mg/m on days 1 and 15 and carboplatin at an area under the curve (AUC) of 6 on day 1 every 4 weeks for at least three cycles. RESULTS: Fifty patients were treated with median of three cycles (range 1-6). Grade 3/4 toxicities included neutropenia in 18 patients (36%), thrombocytopenia in 4 patients (8%), and anemia in 10 patients (20%). No patient experienced febrile neutropenia. Nonhematological toxicities were also mild to moderate, and there were no treatment-related deaths. The overall response rate was 30%, and the disease control rate was 70%. Among the elderly population, 54% of patients achieved partial response. Median progression-free survival was 4.8 months, and median overall survival was 11.8 months. CONCLUSIONS: Biweekly docetaxel plus carboplatin has a similar efficacy and lower toxicity compared with a standard triweekly regimen of docetaxel plus carboplatin, which is a suitable regimen for outpatients, including elderly patients.
KW - Biweekly
KW - Carboplatin
KW - Chemotherapy
KW - Docetaxel
KW - Non-small cell lung cancer
KW - Phase II trial
UR - http://www.scopus.com/inward/record.url?scp=34247847907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247847907&partnerID=8YFLogxK
U2 - 10.1097/01243894-200611000-00010
DO - 10.1097/01243894-200611000-00010
M3 - Article
C2 - 17409982
AN - SCOPUS:34247847907
VL - 1
SP - 979
EP - 983
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
SN - 1556-0864
IS - 9
ER -